Similar articles

• Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.

  Tian H, Xiao Y, Qin L, Chen YH. Tian H, et al. Immunobiology. 2001 Dec;204(4):434-41. doi: 10.1078/0171-2985-00053. Immunobiology. 2001. PMID: 11776398
• [Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies].

  Granados-González V, Piedrahita LD, Martínez M, Genin C, Riffard S, Urcuqui-Inchima S. Granados-González V, et al. Enferm Infecc Microbiol Clin. 2009 Nov;27(9):523-30. doi: 10.1016/j.eimc.2008.02.010. Epub 2009 May 1. Enferm Infecc Microbiol Clin. 2009. PMID: 19409660 Review. Spanish.
• Induction of high levels of epitope-specific antibodies by epitope/peptide candidate vaccines against human immunodeficiency virus type-1 (HIV-1).

  Yu T, Bai Y, Dierich MP, Chen YH. Yu T, et al. Microbiol Immunol. 2000;44(2):105-10. doi: 10.1111/j.1348-0421.2000.tb01253.x. Microbiol Immunol. 2000. PMID: 10803497
• Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.

  Chakraborty K, Durani V, Miranda ER, Citron M, Liang X, Schleif W, Joyce JG, Varadarajan R. Chakraborty K, et al. Biochem J. 2006 Nov 1;399(3):483-91. doi: 10.1042/BJ20060588. Biochem J. 2006. PMID: 16827663 Free PMC article.
• The implications of antigenic diversity for vaccine development.

  Zolla-Pazner S, Gomy MK, Nyambi PN. Zolla-Pazner S, et al. Immunol Lett. 1999 Mar;66(1-3):159-64. doi: 10.1016/s0165-2478(98)00176-x. Immunol Lett. 1999. PMID: 10203049 Review.